Literature DB >> 2578578

Neutralizing monoclonal antibodies to Theiler's murine encephalomyelitis viruses.

S Nitayaphan, M M Toth, R P Roos.   

Abstract

Theiler's murine encephalomyelitis viruses (TMEV) are serologically related picornaviruses which cause both enteric and neurological disease in mice. The biological activities of TMEV vary between the two different TMEV subgroups (TO and GDVII) and with different passage histories of the same TMEV strain (e.g., mouse brain-passed versus tissue culture-passed DA strain of the TO subgroup). We raised neutralizing monoclonal antibodies (mAbs) against tissue culture-passed DA and GDVII strains of TMEV. We produced two mAbs against the DA strain which neutralized all members of the TO subgroup, but not the GDVII subgroup strains (GDVII and FA); these two DA mAbs reacted similarly with both mouse brain-passed DA and tissue culture-passed DA. Of six neutralizing GDVII mAbs, four reacted only to GDVII and FA, whereas two neutralized TO strains as well. These mAbs demonstrate the presence of TMEV group-specific as well as subgroup-specific neutralization and substantiate the division of TMEV into two distinct subgroups. On Western immunoblots one of the two DA mAbs reacted against isolated DA VP1, two GDVII mAbs (which were TMEV group specific) reacted against isolated GDVII VP1 and DA VP1, and the other DA mAb and four other GDVII mAbs required an intact virion conformation for reactivity. An analysis of the epitopes recognized by these mAbs may elucidate sites important in TMEV biological activities.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2578578      PMCID: PMC254681     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  31 in total

1.  Theiler's virus infection in mice: an unusual biphasic disease process leading to demyelination.

Authors:  H L Lipton
Journal:  Infect Immun       Date:  1975-05       Impact factor: 3.441

2.  Central nervous system immunity in mice infected with theiler's virus. I. Local neutralizing antibody response.

Authors:  H L Lipton; F Gonzalez-Scarano
Journal:  J Infect Dis       Date:  1978-02       Impact factor: 5.226

3.  Characterization of the TO strains of Theiler's mouse encephalomyelitis viruses.

Authors:  H L Lipton
Journal:  Infect Immun       Date:  1978-06       Impact factor: 3.441

4.  Selective suppression of reactivity to rat histocompatibility antigens by hybridoma antibodies.

Authors:  T J McKearn; M Sarmiento; A Weiss; F P Stuart; F W Fitch
Journal:  Curr Top Microbiol Immunol       Date:  1978       Impact factor: 4.291

5.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

6.  The detection of DNA-binding proteins by protein blotting.

Authors:  B Bowen; J Steinberg; U K Laemmli; H Weintraub
Journal:  Nucleic Acids Res       Date:  1980-01-11       Impact factor: 16.971

7.  Persistent Theiler's murine encephalomyelitis virus infection in mice depends on plaque size.

Authors:  H L Lipton
Journal:  J Gen Virol       Date:  1980-01       Impact factor: 3.891

8.  Theiler's virus-induced demyelination: prevention by immunosuppression.

Authors:  H L Lipton; M C Dal Canto
Journal:  Science       Date:  1976-04-02       Impact factor: 47.728

9.  Demyelinative myelopathy in mice induced by the DA virus.

Authors:  J R Lehrich; B G Arnason; F H Hochberg
Journal:  J Neurol Sci       Date:  1976-10       Impact factor: 3.181

10.  The TO strains of Theiler's viruses cause "slow virus-like" infections in mice.

Authors:  H L Lipton; M C Dal Canto
Journal:  Ann Neurol       Date:  1979-07       Impact factor: 10.422

View more
  22 in total

1.  The leader polypeptide of Theiler's murine encephalomyelitis virus is required for the assembly of virions in mouse L cells.

Authors:  C Badshah; M A Calenoff; K Rundell
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

2.  Different strains of Theiler's murine encephalomyelitis virus antagonize different sites in the type I interferon pathway.

Authors:  Spyridon Stavrou; Zongdi Feng; Stanley M Lemon; Raymond P Roos
Journal:  J Virol       Date:  2010-07-07       Impact factor: 5.103

3.  Pathogenesis of early and late disease in mice infected with Theiler's virus, using intratypic recombinant GDVII/DA viruses.

Authors:  M Rodriguez; R P Roos
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

4.  Polyprotein processing of Theiler's murine encephalomyelitis virus.

Authors:  R P Roos; W P Kong; B L Semler
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

5.  Critical epitopes in transmissible gastroenteritis virus neutralization.

Authors:  G Jiménez; I Correa; M P Melgosa; M J Bullido; L Enjuanes
Journal:  J Virol       Date:  1986-10       Impact factor: 5.103

6.  Trypsin-sensitive neutralization site on VP1 of Theiler's murine encephalomyelitis viruses.

Authors:  Y Ohara; A Senkowski; J L Fu; L Klaman; J Goodall; M Toth; R P Roos
Journal:  J Virol       Date:  1988-09       Impact factor: 5.103

7.  Infectious cDNA clones of the DA strain of Theiler's murine encephalomyelitis virus.

Authors:  R P Roos; S Stein; Y Ohara; J L Fu; B L Semler
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

8.  Theiler's murine encephalomyelitis virus L* amino acid position 93 is important for virus persistence and virus-induced demyelination.

Authors:  Spyridon Stavrou; Gleb Baida; Ekaterina Viktorova; Ghanashyam Ghadge; Vadim I Agol; Raymond P Roos
Journal:  J Virol       Date:  2009-11-18       Impact factor: 5.103

9.  TGF-beta1 suppresses T cell infiltration and VP2 puff B mutation enhances apoptosis in acute polioencephalitis induced by Theiler's virus.

Authors:  Ikuo Tsunoda; Jane E Libbey; Robert S Fujinami
Journal:  J Neuroimmunol       Date:  2007-09-04       Impact factor: 3.478

10.  Localization of a neutralization site of Theiler's murine encephalomyelitis viruses.

Authors:  S Nitayaphan; M M Toth; R P Roos
Journal:  J Virol       Date:  1985-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.